-
公开(公告)号：US10072089B2
公开(公告)日：2018-09-11
申请号：US15386141
申请日：2016-12-21
申请人： Domantis Limited
IPC分类号： A61K39/395 , C07K16/28 , A61K9/16 , A61K9/00 , C07K16/00 , C07K16/22 , A61M11/00 , A61M15/08
CPC分类号： C07K16/2878 , A61K9/007 , A61K9/0078 , A61K9/1623 , A61K9/1641 , A61K39/3955 , A61K2039/544 , A61M11/005 , A61M15/08 , A61M16/14 , C07K16/00 , C07K16/005 , C07K16/22 , C07K16/2866 , C07K2317/565 , C07K2317/567 , C07K2317/569 , C07K2317/64 , C07K2317/73 , C07K2317/76 , C07K2317/90 , C07K2317/92 , C07K2317/94
摘要： The invention relates to anti-TNFR1 polypeptides and antibody single variable domains (dAbs) that are resistant to degradation by a protease, as well as antagonists comprising these. The polypeptides, dAbs and antagonists are useful for as therapeutics and/or prophylactics that are likely to encounter proteases when administered to a patient, for example for pulmonary administration, oral administration, delivery to the lung and delivery to the GI tract of a patient, as well as for treating inflammatory disease, such as arthritis or COPD.
-
公开(公告)号：US20150087813A1
公开(公告)日：2015-03-26
申请号：US14173204
申请日：2014-02-05
申请人： Domantis Limited
发明人： Kevin MOULDER , Ian Tomlinson
IPC分类号： C07K16/18
CPC分类号： C07K16/18 , C07K16/241 , C07K16/2875 , C07K16/2878 , C07K16/40 , C07K16/42 , C07K2317/21 , C07K2317/31 , C07K2317/34 , C07K2317/53 , C07K2317/55 , C07K2317/565 , C07K2317/567 , C07K2317/569 , C07K2317/622 , C07K2317/626 , C07K2317/92 , C07K2318/20
摘要： The invention provides a dual-specific ligand comprising a first immunoglobulin variable domain having a first binding specificity and a complementary or non-complementary immunoglobulin variable domain having a second binding specificity.
摘要翻译： 本发明提供了包含具有第一结合特异性的第一免疫球蛋白可变结构域和具有第二结合特异性的互补或非互补免疫球蛋白可变结构域的双重特异性配体。
-
公开(公告)号：US08981072B2
公开(公告)日：2015-03-17
申请号：US14101441
申请日：2013-12-10
发明人： Steven G. Nadler , James K. Tamura , Laura Price , Robert P. Rehfuss , Suzanne J. Suchard , Anish Suri , James William Bryson , Aaron Yamniuk , Steven Grant , Olga Ignatovich , Philip Drew
IPC分类号： C12N15/13 , C12N15/12 , C12N5/10 , C07K16/28 , A61K39/395 , A61K45/06 , C07K16/46 , A61K39/00 , A61K38/00
CPC分类号： C07K16/2878 , A61K38/00 , A61K39/3955 , A61K45/06 , A61K2039/505 , A61K2039/545 , C07K16/18 , C07K16/283 , C07K16/2833 , C07K16/2875 , C07K16/2896 , C07K16/46 , C07K16/468 , C07K2317/21 , C07K2317/31 , C07K2317/34 , C07K2317/52 , C07K2317/565 , C07K2317/567 , C07K2317/569 , C07K2317/71 , C07K2317/76 , C07K2317/92 , C07K2317/94 , C07K2319/00 , C07K2319/30
摘要： Antibody polypeptides that specifically bind human CD40L are provided. The antibody polypeptides do not activate platelets. The antibody polypeptides are useful in the treatment of diseases involving CD40L activation, such as graft-related diseases and autoimmune diseases. The antibody polypeptides may be domain antibodies (dAbs) comprising a single VH or VK domain. The half-life of the antibody polypeptides may be increased by modifying the antibody polypeptides to be dual specific reagents that can also bind human serum albumin (HSA) or another antigen.
摘要翻译： 提供了特异性结合人CD40L的抗体多肽。 抗体多肽不激活血小板。 抗体多肽可用于治疗涉及CD40L活化的疾病，例如移植物相关疾病和自身免疫性疾病。 抗体多肽可以是包含单个VH或VK结构域的结构域抗体（dAb）。 抗体多肽的半衰期可以通过将抗体多肽修饰为也可以结合人血清白蛋白（HSA）或另一抗原的双特异性试剂来增加。
-
公开(公告)号：US08779107B2
公开(公告)日：2014-07-15
申请号：US13125332
申请日：2009-10-19
IPC分类号： C07K16/00 , C12P21/08 , A61K39/395 , A61K9/127
CPC分类号： A61K39/3955 , A61K38/217 , A61K39/0011 , A61K2039/55516 , A61K2039/55555 , A61K2039/6018 , C07K14/4748 , C07K16/2851 , C07K2317/22 , C07K2317/569
摘要： The present disclosure relates to a composition for targeting dendritic cells. In particular, the present disclosure relates to a composition comprising: a) one or more antigens; b) an anti-DC-SIGN immunoglobulin single variable domain; and c) a carrier which carries a) and b). The disclosure further relates to formulations, compositions and devices comprising such anti-DC-SIGN molecules and their use as a medicament and in the treatment of cancer, suitably melanoma.
摘要翻译： 本公开涉及用于靶向树突状细胞的组合物。 特别地，本公开涉及一种组合物，其包含：a）一种或多种抗原; b）抗DC-SIGN免疫球蛋白单可变区; 和c）承载a）和b）的载体。 本公开还涉及包含这种抗DC-SIGN分子的制剂，组合物和装置及其作为药物的用途，以及用于治疗癌症，适当地为黑素瘤。
-
公开(公告)号：US20130216538A1
公开(公告)日：2013-08-22
申请号：US13733675
申请日：2013-01-03
申请人： Domantis Limited
发明人： Olga Ignatovich , Benjamin Woolven , Rudolf Maria Theodora De Wildt , Steven Grant , Philip C. Jones , Amrik Basran , Neil Brewis
CPC分类号： C07K16/468 , A61K2039/505 , C07K16/18 , C07K16/22 , C07K16/241 , C07K16/2866 , C07K16/2878 , C07K16/40 , C07K2317/34 , C07K2317/40 , C07K2317/55 , C07K2317/569 , C07K2317/622 , C07K2317/92 , C07K2317/94
摘要： The invention relates to compositions and methods for treating inflammatory disorders. More specifically, the invention relates to antibody compositions and their use in the treatment of inflammatory disorders.
摘要翻译： 本发明涉及用于治疗炎症性疾病的组合物和方法。 更具体地，本发明涉及抗体组合物及其在治疗炎症性疾病中的用途。
-
公开(公告)号：US20130095109A1
公开(公告)日：2013-04-18
申请号：US13650493
申请日：2012-10-12
发明人： Steven G. NADLER , James K. TAMURA , Laura PRICE , Robert P. REHFUSS , Suzanne J. SUCHARD , Anish SURI , James William BRYSON , Aaron YAMNIUK , Steven GRANT , Olga IGNATOVICH , Philip DREW
IPC分类号： C07K16/28 , A61K39/395 , A61K45/06 , C07K16/46
CPC分类号： C07K16/2878 , A61K38/00 , A61K39/3955 , A61K45/06 , A61K2039/505 , A61K2039/545 , C07K16/18 , C07K16/283 , C07K16/2833 , C07K16/2875 , C07K16/2896 , C07K16/46 , C07K16/468 , C07K2317/21 , C07K2317/31 , C07K2317/34 , C07K2317/52 , C07K2317/565 , C07K2317/567 , C07K2317/569 , C07K2317/71 , C07K2317/76 , C07K2317/92 , C07K2317/94 , C07K2319/00 , C07K2319/30
摘要： Antibody polypeptides that specifically bind human CD40L are provided. The antibody polypeptides do not activate platelets. The antibody polypeptides are useful in the treatment of diseases involving CD40L activation, such as graft-related diseases and autoimmune diseases. The antibody polypeptides may be domain antibodies (dAbs) comprising a single VH or VK domain. The half-life of the antibody polypeptides may be increased by modifying the antibody polypeptides to be dual specific reagents that can also bind human serum albumin (HSA) or another antigen.
-
公开(公告)号：US20100254995A1
公开(公告)日：2010-10-07
申请号：US12663501
申请日：2008-06-03
申请人： Michael Steward , Malgorzata Pupecka , Ian Thomlinson , Carolyn Enever , Laurent Jespers , Thil Dinuk Batuwangala
发明人： Michael Steward , Malgorzata Pupecka , Ian Thomlinson , Carolyn Enever , Laurent Jespers , Thil Dinuk Batuwangala
IPC分类号： A61K39/395 , C07K16/22 , C07K14/00 , A61P37/00 , A61P35/00 , A61P29/00 , A61P1/00 , A61P31/04
CPC分类号： C07K16/2878 , A61K9/007 , A61K9/0078 , A61K9/1623 , A61K9/1641 , A61K39/3955 , A61K2039/544 , A61M11/005 , A61M15/08 , A61M16/14 , C07K16/00 , C07K16/005 , C07K16/22 , C07K16/2866 , C07K2317/565 , C07K2317/567 , C07K2317/569 , C07K2317/64 , C07K2317/73 , C07K2317/76 , C07K2317/90 , C07K2317/92 , C07K2317/94
摘要： The invention relates to anti-VEGF polypeptides and antibody single variable domains (dAbs) that are resistant to degradation by a protease, as well as antagonists comprising these. The polypeptides, dAbs and antagonists are useful for pulmonary administration, oral administration, delivery to the lung and delivery to the GI tract of a patient, as well as for treating cancer and inflammatory disease, such as arthritis.
-
公开(公告)号：US20100234570A1
公开(公告)日：2010-09-16
申请号：US11501546
申请日：2006-08-08
申请人： Kevin Moulder , Ian Tomlinson
发明人： Kevin Moulder , Ian Tomlinson
IPC分类号： C07K16/00
CPC分类号： C07K16/18 , C07K16/241 , C07K16/2875 , C07K16/2878 , C07K16/40 , C07K16/42 , C07K2317/21 , C07K2317/31 , C07K2317/34 , C07K2317/53 , C07K2317/55 , C07K2317/565 , C07K2317/567 , C07K2317/569 , C07K2317/622 , C07K2317/626 , C07K2317/92 , C07K2318/20
摘要： The invention provides a dual-specific ligand comprising a first immunoglobulin variable domain having a first binding specificity and a complementary or non-complementary immunoglobulin variable domain having a second binding specificity.
摘要翻译： 本发明提供了包含具有第一结合特异性的第一免疫球蛋白可变结构域和具有第二结合特异性的互补或非互补免疫球蛋白可变结构域的双重特异性配体。
-
公开(公告)号：US20090203542A1
公开(公告)日：2009-08-13
申请号：US12246741
申请日：2008-10-07
CPC分类号： C40B40/02 , C07K2319/02 , C07K2319/41 , C07K2319/43 , C07K2319/50 , C07K2319/70 , C07K2319/735 , C12N15/1037 , C12N15/62
摘要： The present invention concerns a method for the selection of a virus comprising the steps of: (a) providing a virus encoding and displaying a fusion polypeptide, said fusion polypeptide comprising a heterologous polypeptide inserted into the sequence of a viral coat protein polypeptide, wherein said virus comprises a cleavable site located within a displayed polypeptide; (b) exposing the virus to a cleaving agent; (c) propagating the virus comprising intact fusion protein.
摘要翻译： 本发明涉及一种选择病毒的方法，包括以下步骤：（a）提供编码和显示融合多肽的病毒，所述融合多肽包含插入到病毒外壳蛋白多肽序列中的异源多肽，其中所述 病毒包含位于显示的多肽内的可切割位点; （b）将病毒暴露于裂解剂; （c）扩增包含完整融合蛋白的病毒。
-
公开(公告)号：US20090176209A1
公开(公告)日：2009-07-09
申请号：US11654820
申请日：2007-01-17
申请人： Armin Sepp , Andrew Griffiths
发明人： Armin Sepp , Andrew Griffiths
CPC分类号： C12N15/1075 , C07K2319/41 , C07K2319/43 , C07K2319/50
摘要： The present invention to a nucleotide sequence encoding one or more Arc DNA binding domains, one or more Arc DNA binding sites and at least one polypeptide domain.
摘要翻译： 本发明涉及编码一个或多个Arc DNA结合结构域，一个或多个Arc DNA结合位点和至少一个多肽结构域的核苷酸序列。
-
-
-
-
-
-
-
-
-
搜索结果
92 条记录 (耗时 0.061 秒)
